#Margetuximab failed to improve OS in patients with pretreated HER2- positive metastatic #breast_cancer in the final overall survival analysis of SOPHIA trial.

In the phase III randomized trial that was recently published in the JCO, 536 patients were randomized to chemotherapy plus either margetuximab (15 mg/kg IV every 3 weeks or trastuzumab (6 mg/kg IV every 3 weeks after a loading dose of 8 mg/kg. Primary end points were progression-free survival, and OS.

The median OS was 21.6 months with margetuximab versus 21.9 months with trastuzumab (HR: 0.95; P = .620)